AnPac Bio-Medical Science Co., Ltd. (ANPC) |
| 4.3 -0.14 (-3.15%) 05-19 15:59 |
| Open: | 4.57 |
| High: | 4.63 |
| Low: | 4.25 |
| Volume: | 35,704 |
| Market Cap: | 27(M) |
| PE Ratio: | -0.38 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 24.53 |
| Resistance 1: | 21.00 |
| Pivot price: | 18.85 |
| Support 1: | 19.08 |
| Support 2: | 17.89 |
| 52w High: | 11.99 |
| 52w Low: | 2.6 |
AnPac Bio-Medical Science Co., Ltd. is a biotechnology firm that specializes in developing and commercializing tests designed for the early detection and screening of various cancer types. These diagnostic tools leverage the company's unique Cancer Differentiation Analysis (CDA) technology and associated devices. AnPac Bio primarily provides these solutions to corporate entities and life insurance companies across the People's Republic of China. Additionally, the company extends its offerings to include comprehensive physical examination package services. AnPac Bio was established in 2010 and maintains its main operational base in Lishui, China.
Financials
| EPS | 0.760 |
| Book Value | 5.140 |
| PEG Ratio | 0.00 |
| Gross Profit | 23.341 |
| Profit Margin (%) | 0.65 |
| Operating Margin (%) | 1.50 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Thu, 30 Apr 2020
ANPC: A Blood Test for Cancer Diagnosis - scr.zacks.com
Thu, 30 Jan 2020
AnPac Bio Announces Pricing of Initial Public Offering - PR Newswire
Mon, 13 Jul 2026
Mon, 13 Jul 2026
Mon, 13 Jul 2026
Mon, 13 Jul 2026
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
